文献速递慢性肾脏病急性肾损伤血液净化与透析

癌症患者肾衰竭风险:韩国人群队列研究

Risk of Kidney Failure in Patients With Cancer: A South Korean Population-Based Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2021-08-17

基于韩国国民健康保险服务数据库的回顾性人群队列研究,纳入2,473,095名有或无癌症登记的参与者,按年龄、性别、eGFR、糖尿病和高血压为每例癌症患者匹配2名对照。竞争风险分析显示癌症与肾衰竭替代治疗(KFRT)风险升高独立相关( adjusted HR 2.29,95%CI 2.20-2.39),多发性骨髓瘤风险最高。

要点

  • 癌症患者KFRT发生率为1.07/1000人年,无癌症对照为0.51/1000人年。
  • 校正其他潜在预测因素后,癌症与KFRT风险升高显著相关(aHR 2.29,95%CI 2.20-2.39)。
  • 多发性骨髓瘤、白血病、淋巴瘤及肾癌、卵巢癌、肝癌与KFRT风险升高关联最显著,多发性骨髓瘤在各年龄和性别组中风险最高。

核心结论

  • 癌症患者KFRT风险升高,尤其在考虑死亡竞争风险后,多发性骨髓瘤患者风险最高。

研究设计与样本

  • 回顾性人群队列研究,纳入韩国国民健康保险服务数据库2,473,095名参与者,其中癌症824,365例、无癌症1,648,730例,按年龄、性别、eGFR、糖尿病和高血压1:2匹配对照。

主要发现

  • 癌症患者KFRT发生率为1.07/1000人年,无癌症对照为0.51/1000人年。
  • 竞争风险分析显示癌症与KFRT风险升高独立相关(aHR 2.29,95%CI 2.20-2.39)。
  • 多发性骨髓瘤、白血病、淋巴瘤及肾癌、卵巢癌、肝癌与KFRT风险升高关联最显著。
  • 多发性骨髓瘤在各年龄和性别组中KFRT风险最高。
  • 按年龄、性别、吸烟、饮酒、运动、肥胖及合并症划分的所有癌症亚组均显示KFRT风险升高。

临床怎么用

  • 肾内科接诊癌症患者时应关注肾功能监测与KFRT风险评估,多发性骨髓瘤等高危癌种尤需重视。

局限性

  • 无法确认癌症与肾脏结局之间的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Reduced kidney function is associated with an increased risk of cancer; however, it is unclear if cancer increases the risk of kidney failure with replacement therapy (KFRT). We assessed the risk of KFRT among patients with various types of cancer collectively and with specific types of cancer. STUDY DESIGN: Retrospective population-based cohort study. SETTING & PARTICIPANTS: A total of 2,473,095 participants with (n = 824,365) or without (n = 1,648,730) cancer registered in the Korean National Health Insurance Service database. PREDICTORS: Cancer and cancer subtypes defined using International Classification of Diseases, 10th Revision, Clinical Modification, codes. OUTCOMES: Primary outcome was KFRT defined as the initiation of hemodialysis or peritoneal dialysis or kidney transplantation. ANALYTICAL APPROACH: For each patient with cancer, 2 controls matched for age, sex, estimated glomerular filtration rate, diabetes, and hypertension were included. To address the competing risk of death, a competing risk survival analysis was conducted using the Fine and Gray method. RESULTS: Occurrence of KFRT was higher in patients with cancer than in controls without cancer (incidence rates of 1.07 vs 0.51 cases per 1,000 person-years). Competing risk analysis showed that cancer was significantly associated with an increased risk of KFRT after adjusting for other potential predictors (adjusted hazard ratio, 2.29 [95% CI, 2.20-2.39]). Multiple myeloma, leukemia, lymphoma, and kidney, ovarian, and liver cancer were most significantly associated with an increased KFRT risk, with multiple myeloma conferring the highest risk across age and sex groups. All subgroups of patients with cancer (based on age, sex, smoking, alcohol, exercise, obesity, and comorbid conditions) exhibited a higher risk of KFRT. LIMITATIONS: Causal association between cancer and kidney outcomes could not be confirmed. CONCLUSIONS: Patients with cancer, particularly those with multiple myeloma, exhibited an increased risk of KFRT after accounting for the competing risk of death.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kim CS, Kim B, Suh SH, et al. Risk of Kidney Failure in Patients With Cancer: A South Korean Population-Based Cohort Study. Am J Kidney Dis. 2021. PMID: 34416352. doi:10.1053/j.ajkd.2021.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。